Glaucoma News and Research

Latest Glaucoma News and Research

First human gene mutation that causes extreme farsightedness

Working with an Amish-Mennonite family tree, Johns Hopkins researchers at the Wilmer Eye Institute have discovered what appears to be the first human gene mutation that causes extreme farsightedness.

24 Aug 2005

Radiation helps eye cancer patients retain vision

Doctors in the United Kingdom have determined that patients suffering from cancer affecting their eye can usually avoid visual handicap, loss of the eye and spread of the disease by receiving proton beam radiation therapy, according to a new study

1 Aug 2005

Major advances in the global fight against eye disease

Now research offering a better understanding of the genetics controlling endemic eye diseases will be advanced by an international collaboration between Cardiff University’s School of Optometry and Vision Sciences and the Department of Opthalmology, Kyoto Prefectural University of Medicine, Japan.

6 Jun 2005

Older adults with diabetes in managed care networks have higher rates of untreated eye disease

Medicare beneficiaries at high risk for eye disease due to diabetes are more likely to have unrecognized and untreated eye disease if they are enrolled in managed care than if they have fee-for-service (FFS) health insurance, according to an article in the May issue of Archives of Ophthalmology.

9 May 2005

Glaucoma therapy patients often do not comply with their doctor’s prescribed medicine regimen

A study that appears in the May edition of Ophthalmology, the clinical journal of the American Academy of Ophthalmology, shows that as many as 47 percent of patients receiving glaucoma therapy do not comply with their doctor’s prescribed medicine regimen. This is in startling contrast to the 90 percent of doctors who believe that their patients are following the prescribed treatment.

2 May 2005

Glaucoma therapy recipients do not comply with doctor's prescribed medicine regimen

A study that appears in the May edition of Ophthalmology, the clinical journal of the American Academy of Ophthalmology, shows that as many as 47 percent of patients receiving glaucoma therapy do not comply with their doctor's prescribed medicine regimen. This is in startling contrast to the 90 percent of doctors who believe that their patients are following the prescribed treatment.

1 May 2005

High-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked development of glaucoma

In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.

14 Mar 2005

Scientists have regenerated a damaged optic nerve

This achievement, which occurred in laboratory mice and is described in the March 1, 2005 issue of the Journal of Cell Science, holds great promise for victims of diseases that destroy the optic nerve, and for sufferers of central nervous system injuries.

24 Feb 2005

Oak Ridge technology used to understand semiconductor defects helps people at risk of becoming blind

Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

10 Feb 2005

FDA approves Enablex for the treatment of overactive bladder

Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

22 Dec 2004

Confusion over Lasik eye surgery terminology

The Eye Surgery Education Council of the American Society of Cataract and Refractive Surgery Foundation today issued a clarification on the use of the terms "wavefront-guided," and "wavefront-optimized" in connection with laser-based procedures (LASIK, PRK, etc.) and implantable lenses used for vision correction purposes.

20 Dec 2004

Detrol LA significantly reduces symptoms of overactive bladder

Pfizer today announced results of a comprehensive six-year review of efficacy and safety data for Detrol LA (tolterodine tartrate extended release capsules) indicating that Detrol LA significantly reduces symptoms of overactive bladder (OAB) with a low occurrence of side effects, and should be considered first-line therapy.

13 Dec 2004

Instructions provided with medicines is far too small for people with impaired or partially sighted vision to read

When you're in your local pharmacy, do you ever try to compare the lables on products, only to find that the print is impossible to read? A new study goes a little way to remedy this, at least for those who are visually impaired.

16 Nov 2004

Computer use may be linked to the development of glaucoma

So, you spend all or part of your day working with computers. Then take notice, a new Japanese study has found that computer use may be linked to the development of glaucoma (an increase in fluid pressure inside the eye that may lead to loss of vision), especially among those who are short sighted.

16 Nov 2004

McGuinty Government introduces changes to eye care services

The McGuinty government is making changes to the way OHIP insures routine eye exams, Health and Long-Term Care Minister George Smitherman announced today.

1 Nov 2004

Drug-loaded contact lenses to treat eye diseases

When a person suffers from eye ailments today, nine times out of ten, he will be prescribed eye drops to treat his illness or relieve his discomfort.

29 Oct 2004

A unique new non-invasive technique for high resolution optical imaging of the eye

The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University’s Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.

12 Oct 2004